Current evidence-based therapy does not restore plasma apelin level in phenotypically diverse chronic heart failure patients

Vinu Wilson1*, Pankaj Prabhakar2, Sandeep Seth3, Subir K. Maulik2

1Department of Pharmacology, Sree Gokulam Medical College and Research Foundation, Venjaramoodu, Thiruvananthapuram, Kerala, India
2Department of Pharmacology, 3Department of Cardiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India

Received: 21 November 2016
Accepted: 26 December 2016

*Correspondence to:
Dr. Vinu Wilson,
Email: vinuwilson85@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Apelin, endogenous peptide acting through its receptor (APJ), is the most potent inotropic agent known to man. Plasma apelin and cardiac APJ mRNA levels rise in early stages of chronic heart failure (CHF) but fall later in decompensated CHF. The effect of current evidence-based management of CHF on plasma apelin level is not known. We estimated change in plasma apelin level in CHF patients of diverse phenotypes treated with standard pharmacotherapy and compared it with the corresponding change in left ventricular ejection fraction (LVEF), plasma brain natriuretic peptide (BNP) level and quality of life (QoL).

Methods: With ethical approval and written informed consent, venous blood samples were collected from 39 CHF (dilated cardiomyopathy (DCM) (n=21), restrictive cardiomyopathy (RCM) (n=9) and chronic constrictive pericarditis (CCP) (n=9)) patients and 10 age-matched healthy controls, at baseline and after 12 weeks. Plasma apelin and BNP were estimated by competitive ELISA (RayBiotech Inc.) and an auto-analyzer (Triage, Allere Inc., respectively). QoL was assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ). Nonparametric tests were applied and p-value <0.05 was considered significant.

Results: Low LVEF, KCCQ score and high BNP levels were observed in all CHF patients compared to controls. Plasma apelin level was depressed in RCM and CCP patients compared to controls but not in DCM patients. These parameters did not change in any group after 3 months of standard pharmacotherapy.

Conclusions: Current evidence-based management of CHF does not restore the depressed apelin-APJ axis. New drugs are required for specifically modulating this promising therapeutic target in CHF.

Keywords: APJ, Adipokine, Heart failure, Neurohormone

INTRODUCTION

Chronic heart failure (CHF) is a morbid complication of cardiovascular diseases (CVD) of diverse etiologies. The prevalence of CHF is rising worldwide due to effective treatment of acute cardiovascular events resulting in improved rates of patient survival. The widely accepted neurohormonal model of chronic heart failure implicates several biological molecules as either favouring or opposing the pathological progression of the disease. One among these, the Brain natriuretic peptide (BNP), is now an established biomarker for diagnosis, risk stratification and monitoring of therapy in heart failure with reduced ejection fraction (HFrEF).1

Worldwide, research is being undertaken to identify novel biomarkers in CHF to facilitate early diagnosis, assessment of prognosis and possible therapeutic targeting. Apelin is one among several such endogenous substances with putative role in the pathophysiology of CVDs.2 Discovered in 1998 as the endogenous ligand of then orphan APJ receptor, the apelin-APJ system is postulated to counterbalance the renin-angiotensin-aldosterone system (RAAS) mediated adverse

cardiovascular effects in CVDs. Apelin and its receptor are expressed in the human heart, blood vessels, lungs, brain, adipocytes and kidneys. Released from endothelial cells of cardiac blood vessels, it is the most potent endogenous inotropic agent known currently (EC50 33 pmol/L). The inotropic property of apelin is distinct because it is not associated with concomitant tachycardia or cardiac hypertrophy. Apelin also produces nitric oxide (NO)-dependent coronary and systemic vasodilatation, reducing both cardiac preload and afterload. It is endogenously degraded by the carboxypeptidase, angiotensin converting enzyme 2 (ACE2), which also catalyzes production of the vasodilatory peptide, angiotensin 1-7, from angiotensin II. These properties strongly suggest a putative role for apelin in regulation of cardiovascular function in both health and disease.

Several studies have documented changes in plasma apelin level in CVDs, though with some conflicting results. Plasma apelin is found to be reduced in several CVDs including chronic heart failure, essential hypertension, stable angina and myocardial infarction compared to healthy controls. In CHF, plasma apelin level seems to rise in early stages, but to decrease in later stages along with down-regulation of APJ receptors and both have been shown to recover following cardiac mechanical offloading with left ventricular assist devices. However, clinical studies have not monitored whether any change in plasma apelin level occurs in CHF patients being treated with evidence-based pharmacotherapy or following pericardectomy in case of chronic constrictive pericarditis (CCP). In this study, we attempted to assess the response of plasma apelin level to current evidence-based therapy in CHF patients of different phenotypes.

**METHODS**

In this prospective, multiple arm, analytical observational study, CHF patients of diverse phenotypes were consecutively recruited from the heart failure clinic at the department of cardiology, with written informed consent. Ethical approval for the study was granted by the institutional ethics sub-committee (IESC/T-18/04.12.09). The study was registered with the clinical trial registry of India (2009/091/000935). CHF patients of either gender aged between 12 to 80 years, with ≥class II NYHA symptoms and either reduced (HFrEF) (LVEF ≤40%) or preserved (HFrEF) (LVEF >40%) left ventricular ejection fraction (LVEF) were consecutively recruited into the study. Subjects who were apparently healthy on clinical examination with normal laboratory investigation results and an unremarkable echocardiographic study were recruited as controls from among the relatives of the patients. Patients with history of an acute coronary syndrome within the previous one month, diabetes mellitus, severe or uncontrolled hypertension, obesity, hypercholesterolemia, hepatic or renal failure and pregnant or lactating women were excluded from the study.

**Primary outcome measure**

Change in plasma apelin level in CHF patients on evidence-based pharmacotherapy or following pericardectomy (for CCP) over a period of 12 weeks.

**Secondary outcome measures**

(i) Comparison of plasma apelin level in CHF patients versus healthy controls at baseline and (ii) Find correlation, if any, between plasma apelin level versus plasma BNP level, LVEF and quality of life, over a period of 12 weeks.

**Clinical examination and laboratory investigations**

Screening of chronic heart failure patients for eligibility was done based on their clinical history, prior investigation and echocardiography reports not older than one month. Patients fulfilling inclusion and exclusion criteria and willing to participate in the study were asked to report after overnight fasting to the Clinical Pharmacology unit of department of Pharmacology. Patient information sheet was provided (in either Hindi or English language) to the patient and written informed consent was obtained. A blood sample (5 mL) was drawn from the antecubital vein using tourniquet for estimation of fasting blood glucose (FBG), serum total cholesterol, tests of renal (blood urea, serum creatinine) and liver (serum bilirubin, transaminases and serum alkaline phosphatase) function at the central laboratory.

Echocardiography was performed by author SS using adult transthoracic probe (3.5 MHz). Left ventricular (LV) volumes and M-mode measurements (LV end systolic dimension, LV end diastolic dimension, fractional shortening) in parasternal short axis and apical (4 and 2 chamber) views were recorded and stored for offline analysis according to standard guidelines. Quality of life was assessed using the self-administered Kansas City Cardiomyopathy Questionnaire (KCCQ).

**Estimation of plasma apelin**

A portion of the venous blood sample was centrifuged at 3000 rpm at 4°C for 10 minutes. Plasma was separated and frozen in aliquots at -70°C until analysis. Apelin was estimated in duplicate using the apelin-C terminus competitive enzyme linked immunoassay (ELISA) kit (RayBiotech Inc., USA), according to the manufacturers protocol. This assay targets the C-terminus of the 77-amino acid apelin peptide and therefore detects all active forms of apelin including apelin-36, apelin-31, apelin-28 and apelin 13.

**Estimation of plasma BNP**

Plasma BNP was estimated using a point of care device (Triage, Allere Inc., USA) following manufacturer's
protocol. This device has been used validated previously in large clinical trials.¹⁴

**Statistical analysis**

Sample size of at least 8 patients in each group was calculated based on an expected difference of 10% in plasma apelin level due to standard therapy at an alpha level of 0.05 and a power of 90%. However, it was decided to recruit all eligible patients providing consent into the study to improve its validity. Statistical analysis was done using STATA 11.2. Quantitative variables were reported as mean±SD (for normal distribution) or median with interquartile range (IQR) (for non-normal distribution) and categorical variables as counts (n) and frequencies (%). Comparison of baseline values of the groups versus controls was done using t test for normally distributed data or Wilcoxon Rank-sum test for non-normal data. Categorical variables were compared using Chi-square test or Fischer’s exact test. Outcome measures were compared with respective baseline values using either paired t test or Wilcoxon’s signed rank test. A p-value less than 0.05 was considered statistically significant.

**RESULTS**

Table 1: Baseline characteristics of study subjects.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normal Controls (n = 10)</th>
<th>Dilated cardiomyopathy patients (n = 21)</th>
<th>Restrictive cardiomyopathy patients (n = 9)</th>
<th>Constrictive pericarditis patients (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>37 ± 12</td>
<td>43 ± 12</td>
<td>35 ± 14</td>
<td>31 ± 9</td>
</tr>
<tr>
<td>Sex (m:f)</td>
<td>7:3</td>
<td>12:9</td>
<td>4:5</td>
<td>6:3</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.8 ± 2.9</td>
<td>22.2 ± 3.8</td>
<td>20.6 ± 4.5</td>
<td>22.8 ± 3.2</td>
</tr>
<tr>
<td>Pulse rate (/min)</td>
<td>79 ± 7</td>
<td>78 ± 10</td>
<td>70 ± 11</td>
<td>80 ± 7</td>
</tr>
<tr>
<td>Systolic BP (mm of Hg)</td>
<td>115 ± 14</td>
<td>102 ± 7**</td>
<td>100 ± 6**</td>
<td>115 ± 14*</td>
</tr>
<tr>
<td>Diastolic BP (mm of Hg)</td>
<td>74 ± 8</td>
<td>67 ± 5**</td>
<td>64 ± 8**</td>
<td>69 ± 5</td>
</tr>
<tr>
<td>FBG (mg/dL)</td>
<td>97 ± 11</td>
<td>105 ± 25</td>
<td>91 ± 10</td>
<td>95 ± 10</td>
</tr>
<tr>
<td>Blood urea (mg/dL)</td>
<td>23 ± 4</td>
<td>34 ± 13**</td>
<td>33 ± 11*</td>
<td>32 ± 10*</td>
</tr>
<tr>
<td>S. Creatinine (mg/dL)</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.3</td>
<td>1.0 ± 0.2</td>
<td>1.0 ± 0.2</td>
</tr>
<tr>
<td>S. Bilirubin (mg/dL)</td>
<td>0.7 ± 0.2</td>
<td>0.9 ± 0.3</td>
<td>1.1 ± 0.4*</td>
<td>1.1 ± 0.3*</td>
</tr>
<tr>
<td>SGOT (IU/L)</td>
<td>29 ± 8</td>
<td>28 ± 7</td>
<td>43 ± 24</td>
<td>43 ± 16*</td>
</tr>
<tr>
<td>SGPT (IU/L)</td>
<td>31 ± 15</td>
<td>25 ± 11</td>
<td>42 ± 38</td>
<td>39 ± 20</td>
</tr>
<tr>
<td>S. ALP (IU/L)</td>
<td>116 ± 21</td>
<td>120 ± 36</td>
<td>132 ± 49</td>
<td>98 ± 26</td>
</tr>
<tr>
<td>T. Cholesterol (mg/dL)</td>
<td>164 ± 27</td>
<td>171 ± 43</td>
<td>173 ± 47</td>
<td>171 ± 27</td>
</tr>
<tr>
<td>NYHA Class</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II (n = 21)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II (n = 9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>II (n = 8), III (n = 1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>63 ± 3</td>
<td>27 ± 8**</td>
<td>44 ± 13**</td>
<td>55 ± 3**</td>
</tr>
<tr>
<td>KCCQ clinical summary score (%)</td>
<td>100 ± 0</td>
<td>74 ± 16**</td>
<td>67 ± 20**</td>
<td>54 ± 26**</td>
</tr>
<tr>
<td>Plasma BNP (pg/mL)</td>
<td>6 (5, 10)</td>
<td>87 (17, 365)**</td>
<td>520 (276, 1085)**</td>
<td>172 (92, 257)**</td>
</tr>
<tr>
<td>Plasma Apelin (pg/mL)</td>
<td>570 (415, 680)</td>
<td>450 (230, 620)</td>
<td>300 (205, 590)*</td>
<td>380 (230, 420)*</td>
</tr>
<tr>
<td>Loop diuretics (n)</td>
<td>NA</td>
<td>21</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>ACEIs (n)</td>
<td>NA</td>
<td>12</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>ARBs (n)</td>
<td>NA</td>
<td>99</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Beta blockers (n)</td>
<td>NA</td>
<td>17º</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Digoxin (n)</td>
<td>NA</td>
<td>12</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Spironolactone(n)</td>
<td>NA</td>
<td>18</td>
<td>8</td>
<td>5</td>
</tr>
</tbody>
</table>

*p<0.05 compared to control, **p<0.01 compared to control, ºp<0.05 compared to RCM patients.
The prescription profile of drugs in the CHF patients indicated that significantly higher proportion of DCM patients were on Angiotensin II type I receptor blockers (ARBs) and beta adrenergic blockers compared to RCM patients (Table 1). The patients of CCP were on the least number of drugs in consonance with their distinct pathophysiology. Change in the dose of the standard drugs prescribed was not necessitated in any of the CHF patients over the observation period of 12 weeks. However, there was no change in LVEF, plasma BNP, plasma apelin or quality of life of CHF patients on follow-up after 12 weeks (Table 2). In the sole CCP patient who underwent elective pericardial resection, plasma apelin and BNP levels improved from 220 pg/mL and 91.7 pg/mL to 320 pg/mL and 20.2 pg/mL after 12 weeks, respectively. No association was found between plasma apelin levels and LVEF, KCCQ score or plasma BNP levels.

**Table 2: Outcome measures after 12 weeks of standard therapy.**

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Time-point</th>
<th>Dilated cardiomyopathy patients (n=21)</th>
<th>Restrictive cardiomyopathy patients (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEF (%)</td>
<td>Baseline</td>
<td>27 ± 8</td>
<td>44±13</td>
</tr>
<tr>
<td></td>
<td>12 weeks</td>
<td>28 ± 8</td>
<td>45±13</td>
</tr>
<tr>
<td>KCCQ clinical summary score (%)</td>
<td>Baseline</td>
<td>74 ± 16</td>
<td>69 (52, 87)</td>
</tr>
<tr>
<td></td>
<td>12 weeks</td>
<td>76 ± 23</td>
<td>64 (35, 81)</td>
</tr>
<tr>
<td>Plasma BNP (pg/mL)</td>
<td>Baseline</td>
<td>87 (17, 365)</td>
<td>520 (276, 1085)</td>
</tr>
<tr>
<td></td>
<td>12 weeks</td>
<td>119 (14, 237)</td>
<td>752 (490, 2070)</td>
</tr>
<tr>
<td>Plasma Apelin (pg/mL)</td>
<td>Baseline</td>
<td>450 (230, 620)</td>
<td>300 (205, 590)</td>
</tr>
<tr>
<td></td>
<td>12 weeks</td>
<td>380 (275, 550)</td>
<td>360 (240, 390)</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Our study has for the first time shown that plasma apelin levels are reduced in two distinct phenotypes of chronic heart failure viz. restrictive cardiomyopathy (RCM) and chronic constrictive pericarditis (CCP) compared to normal controls. However, they are not restored to normal levels by standard pharmacotherapy over 12 weeks.

The clinical diagnosis of CHF in our patients was confirmed by elevated plasma BNP and significantly reduced LVEF and KCCQ score compared to normal controls. BNP is now widely accepted as a reliable biomarker for diagnosis of decompensated heart failure. It has been recommended as a rapid bedside test to differentiate between underlying primary cardiac versus pulmonary disease presenting as acute dyspnea to emergency departments. It also aids in establishing severity of CHF and in predicting their long term prognosis. LVEF, a surrogate marker of cardiac output, is routinely measured to assess ventricular function and monitor disease progression in CHF patients. However, several studies have shown that LVEF poorly correlates with functional capacity and Quality of Life (QoL) reported by patients. Therefore, clinical studies of CHF have increasingly incorporated patient reported QoL measures such as the KCCQ score for an assessment of patient’s perspectives regarding therapy. Moreover, improvement in scores on QoL questionnaires have been shown to be associated with improvements in patient survival.

Elevated blood urea nitrogen (BUN) observed in the patients may be attributed to reduced renal perfusion in CHF. Though blood urea was elevated, preservation of serum creatinine within clinically normal limits indicated that the patients were not in overt renal failure. Some studies have pointed out that BUN elevation in CHF patients might also be due to increased renal urea reabsorption from distal tubules by non-osmotically released arginine vasopressin (AVP) in worsening CHF. Assessment of renal function was important because both plasma apelin and BNP levels are known to be elevated in renal failure. Elevated serum bilirubin and transaminase levels in CCP and RCM patients could be attributed to hepatic dysfunction secondary to elevated central venous pressure.

The drugs prescribed in the patients were in consonance with the current evidence-based treatment guidelines which advocate a Renin-angiotensin-aldosterone system (RAAS) inhibitor (ACEI / ARB) and a beta adrenergic blocker as standard of care in symptomatic HFrEF patients. However, evidence regarding the possible benefits of these drugs in HFrEF patients is equivocal, thereby making management of comorbidities the major therapeutic goal. This difference in pharmacotherapy reflected in our study as lower proportion of RCM patients were prescribed an ARB and beta blocker compared to DCM patients. On the other hand, the CCP patients were on minimal pharmacotherapy since the definitive treatment is pericardial resection, which was undergone by a lone patient during the study period.

Plasma apelin level was found to be depressed in RCM and CCP while not in DCM patients. Circulating apelin is predominantly synthesized from atria in healthy individuals. In both RCM and CCP, ventricular relaxation is impaired leading to elevated atrial pressure and atrial dilatation. Mechanical stretch has been shown to decrease apelin gene expression in cultured neonatal rat ventricular myocytes. We postulate that stretching of atrial myocytes may analogously decrease atrial apelin synthesis in RCM and CCP patients. In fact, APJ is now recognized as a dual receptor for both apelin and mechanical stretch, with their relative activities biasing its signaling. While apelin signals through APJ in G-protein dependent manner for its cardioprotective effects,
mechanical stretch induces pathologic cardiac hypertrophy by activating APJ dependent extracellular signal-regulated kinase (ERK) phosphorylation and simultaneously depresses apelin signaling by promoting β-arrestin mediated APJ internalization. Moreover, pulmonary hypertension, a common complication in these patients, has also been reported to be associated with low serum apelin levels for less understood reasons.26 It has been shown in both animal and human studies that increased synthesis of apelin accompanies cardiomyocyte hypertrophy in response to hemodynamic stress and that either exhaustion of apelin synthetic machinery or its excessive degradation heralds cardiovascular decompensation.27 Though apelin can override stretch-induced APJ activation, there is lack of compensatory activation of apelin expression in APJ knockout or wild type mice in response to hemodynamic stress.25 This suggests that mechanical stretch acting through different mechanosensors viz. APJ and ATII type 1 receptor induces pathologic cardiac hypertrophy with minimal compensatory up-regulation of apelin synthesis.25,28 The development of dilated ventricles instead of hypertrophy in DCM patients may be related to altered mechanoreceptor signaling or the protective effects of preserved apelin level observed in our study.

The lack of change in LVEF, plasma BNP level or KCCQ score in DCM and RCM patients over 12 weeks of standard pharmacotherapy may seem surprising. It could be due to previous treatment with standard drugs received by these patients referred to our tertiary care hospital so that many of them could have already achieved maximum possible therapeutic benefits of these drugs. Further, the duration of follow-up in our study might have been inadequate to detect slow developing changes in the clinical status of patients. The fact that most of the clinical trials of current heart failure treatments involved follow-up of 4-12 months supports this speculation.29,30 In the same vein, the short period of observation in our study may have been inadequate for development of change in plasma apelin level. However, an alternative hypothesis could be explored. Upregulation of ACE2 in failing hearts may prevent compensatory rise in plasma apelin levels.31 This may happen even in presence of ACEIs which suppress ACE activity but not that of ACE2. Moreover, ACEIs and ARBs have been shown to upregulate ACE2 gene expression after myocardial infarction.32 However, apelin and ACE2 are thought to synergistically antagonize detrimental effects of RAAS signaling. Apelin has been shown to positively regulate ACE2 expression while product of apelin catalysis by ACE2 has been shown to retain its biological effects.33,34 Moreover, Ang 1-7, produced from ATII by ACE2, acts on Mas receptor to induce cardioprotective effects.33 Recently, efforts are being made to develop apelin analogues resistant to ACE2 metabolism as potential drugs in CHF.35 Apelin-APJ axis is thought to be an exciting therapeutic target in CHF because it is a potent positive inotrope which offloads the heart while preventing pathologic cardiac hypertrophy induced by sustained neurohormonal activation. It antagonizes Ang II induced ATII type 1 receptor activation by allosteric trans-inhibition besides opposing the deleterious effects of sustained RAAS activation in CHF.36 Though its plasma levels and cardiac expression are increased in early heart failure, its signaling is impaired in late stages by currently unclear mechanisms. A clinical study of intravenous apelin infusion in healthy volunteers and CHF patients has shown encouraging results.37 Development of pegylated apelin, nano-liposomal apelin and a G-protein biased APJ agonist recently have strengthened the hope for a therapeutic breakthrough in CHF.38-40 Drugs which indirectly accentuate apelin signaling by inhibiting its degradation could theoretically be beneficial in CHF patients.

CONCLUSION

Current evidence-based management of diverse CHF phenotypes does not restore the depressed apelin-APJ axis signaling. New drugs are required for specifically modulating this promising therapeutic target in CHF.

ACKNOWLEDGEMENTS

This work was supported by Indian Council of Medical Research (I.C.M.R.) grant no. 3/2/2010-2/PG-Thesis-MPD-13.

Funding: Indian Council of Medical Research (I.C.M.R.)
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Sub-Committee (IESC/T-18/04.12.09).

REFERENCES

12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr. 2005;18(12):1440-63.


